Chemoradiotherapy for adenoid cystic carcinoma: Preliminary results of an organ sparing approach

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 2, 2006, Pages 153-157

  Haddad, Robert I ^a   Posner, Marshall R ^a   Busse, Paul M ^c   Norris Jr , Charles M ^a   Goguen, Laura A ^a   Wirth, Lori J ^a   Blinder, Russell ^a   Krane, Jeffrey F ^b   Tishler, Roy B ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adenoid cystic carcinoma; Chemoradiotherapy; Organ preservation; Salivary gland neoplasm

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CARBOPLATIN; HISTAMINE H2 RECEPTOR ANTAGONIST; PACLITAXEL; STEROID; ANTINEOPLASTIC AGENT;

ADENOID CYSTIC CARCINOMA; ADULT; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL ARTICLE; ELECTRON THERAPY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MALE; METASTASIS; MUCOSA INFLAMMATION; ORGAN PRESERVATION; PROGNOSIS; REVIEW; SALIVARY GLAND CARCINOMA; TREATMENT OUTCOME; ARTICLE; HEAD AND NECK TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, ADENOID CYSTIC; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33645785404     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000203756.36866.17     Document Type: Review

References (32)

1. Alvi A, Myers E, Carrau R. Malignant tumors of the salivary glands. In: Myers E, Suen J, eds. Cancer of the Head and Neck, 3 ed. Philadelphia: W.B. Saunders; 1996:525-561.
2. Anderson J, Beenken S, Crowe R, et al. Prognostic factors in salivary gland cancer. Head Neck. 1995;17:480-486.
3. Spiro R. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg. 1986;8:177-184.
4. Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg. 1997;174:495-498.
5. Simpson JR, Thawley SE, Matsuba HM. Adenoid cystic salivary gland carcinoma: treatment with irradiation and surgery. Radiology. 1984;151:509-512.
6. Fordice J, Kershaw C, El-Naggar A, et al. Adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1999;125:149-152.
7. Mendenhall WM, Morris CG, Amdur RJ, et al. Radiotherapy alone or combined with surgery for adenoid cyctic carcinoma of the head and neck. Head Neck. 2004;26:154-162.
8. Douglas JG, Laramore GE, Austin-Seymour M, et al. Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Physics. 2000;46:551-557.
9. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced larynx cancer. New Engl J Med. 2003;349:2091-2098.
10. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69-76.
11. Adelstein D, Li Y, Adams G, et al. An Intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92-98.
12. Sutharalingum M, Haas M, Conley B, et al. The use of carboplatinum and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Biol Oncol Physics. 2000;47:49-56.
13. Haddad R, Posner M. Palliative chemotherapy in patients with salivary gland neoplasms: review of the literature and preliminary reports of two recently performed phase II studies with single agents herceptin and gemcitabine. Adv Hematol Oncol. 2003;1:226-228.
14. Dreyfuss A, Clark J, Fallon B, et al. Cyclophosphamide, doxorubicin and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer. 1987;60:2869-2872.
15. Posner M, Ervin T, Weichselbaum R. Chemotherapy of advanced salivary gland neoplasms. Cancer. 1982;50:2261-2264.
16. Airoldi M, Fornari G, Pendani F, et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res. 2000;20:3781-3784.
17. Airoldi M, Bumma C, Bertetto O, et al. Vinorelbine for recurrent adenocarcinoma-like salivary gland malignancies. Oral Oncol Eur J Cancer. 1996;32B:213-214.
18. Creagan ET, Woods JE, Rubin J, et al. Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer. 1988;62:2313-2319.
19. de Haan LD, de Mulder PH, Vermorken JB, et al. Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck. Head Neck. 1992;14:273-277.
20. Licitra L, Cavina R, Grandi C, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol. 1996;7:640-642.
21. Skibba JL, Hurley JD, Ravelo HV. Complete response of a metastatic adenoid cystic carcinoma of the parotid gland to chemotherapy. Cancer. 1981;47:2543-2548.
22. Vernook A, Tseng A, Myers F, et al. Cisplatin, doxorubicin, and 5-fluourouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol. 1987;5:951-955.
23. Vermorken JB, Verweij J, de Mulder PH, et al. Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1993;4:785-788.
24. Tannock IF, Sutherland DJ. Chemotherapy for adenocystic carcinoma. Cancer. 1980;46:452-454.
25. Jennings T, Li Y, Pinto H, et al. Phase II trial of paclitaxel in advanced or metastatic salivary gland malignancies: an Eastern Cooperative Oncology Group Study. Proc Am Soc Clin Oncol. 2001;20:236a.
26. Pignon J, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell cancer: three meta-analysis of updated individual data. Lancet. 2000;355:949-955.
27. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. New Engl J Med. 2004;350:1945-1952.
28. Tishler R, Schiff P, Geard C, et al. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Physics. 1992;22:613-617.
29. Tishler R, Geard C, Hall E, et al. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res. 1992;52:3495-3497.
30. Milas L, Hunter N, Mason K, et al. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res. 1994;54:3506-2510.
31. Milas L, Saito Y, Hunter N, et al. Theraputic potential of paclitaxel-radiation treatment of a murine ovarian carcinoma. Radiother Oncol. 1996;40:163-167.
32. Haddad A, Enepekides DJ, Manolidis S, et al. Adenoid cystic carcinoma of the head and neck: a clinicopathologic study of 37 cases. J Otolaryngol. 1995;24:201-205.